Molecular Templates Inc (NASDAQ:MTEM) shares were up 9.8% during mid-day trading on Friday . The stock traded as high as $6.44 and last traded at $6.27, approximately 190,989 shares were traded during trading. An increase of 113% from the average daily volume of 89,511 shares. The stock had previously closed at $5.71.

Several analysts recently weighed in on the company. ValuEngine downgraded Molecular Templates from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. Zacks Investment Research downgraded Molecular Templates from a “hold” rating to a “sell” rating in a research note on Friday, August 16th. TheStreet downgraded Molecular Templates from a “c-” rating to a “d” rating in a research note on Monday, August 5th. Cowen restated a “buy” rating on shares of Molecular Templates in a research note on Tuesday, August 13th. Finally, BidaskClub downgraded Molecular Templates from a “hold” rating to a “sell” rating in a research note on Friday, July 26th. Three equities research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $13.58.

The firm has a 50 day moving average of $5.50 and a two-hundred day moving average of $6.52. The stock has a market cap of $209.82 million, a P/E ratio of -6.15 and a beta of 2.88. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.11 and a current ratio of 3.11.

Molecular Templates (NASDAQ:MTEM) last announced its earnings results on Monday, August 12th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). Molecular Templates had a negative net margin of 113.85% and a negative return on equity of 27.72%. The business had revenue of $5.45 million for the quarter, compared to the consensus estimate of $6.00 million. On average, sell-side analysts anticipate that Molecular Templates Inc will post -0.92 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in the stock. Susquehanna International Group LLP bought a new stake in Molecular Templates during the 2nd quarter valued at approximately $98,000. Zacks Investment Management acquired a new position in Molecular Templates in the 2nd quarter valued at approximately $307,000. Citadel Advisors LLC acquired a new position in Molecular Templates in the 2nd quarter valued at approximately $111,000. Cubist Systematic Strategies LLC acquired a new position in Molecular Templates in the 2nd quarter valued at approximately $37,000. Finally, Point72 Asset Management L.P. acquired a new position in Molecular Templates in the 2nd quarter valued at approximately $1,682,000. Hedge funds and other institutional investors own 38.07% of the company’s stock.

Molecular Templates Company Profile (NASDAQ:MTEM)

Molecular Templates, Inc, a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma.

See Also: FAANG Stocks

Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.